Latham Advises Norgine on Exclusive Licensing Agreement With X4 Pharmaceuticals

Latham & Watkins has advised Norgine, a leading European specialist pharmaceutical company, on an exclusive licensing and supply agreement with X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system. Under this agreement, Norgine will commercialize Mavorixafor in Europe, Australia, and New Zealand following regulatory approvals. Under the terms of the license and supply agreement, X4 will receive €28.5 million in upfront consideration and up to €226 million contingent upon the achievement of certain regulatory and commercial milestones, in addition to escalating double-digit royalties of up to the mid-twenties on any future net sales in the licensed territories.

Mavorixafor is a selective CXCR4 receptor antagonist approved in the US and marketed by X4 as XOLREMDI®, an oral, once-daily treatment for patients 12 years of age and older with WHIM syndrome, a rare primary immunodeficiency.

The Latham team was led by London associate Oliver Mobasser, with New York counsel Eliot Choy, London partner Robbie McLaren, and associate Edgar Lee.